# Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）

> **NCT06669182** · NA · RECRUITING · sponsor: **Xijing Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Alzheimer Disease
- Transcranial Magnetic Stimulation
- Cerebellum

## Interventions

- **DEVICE:** Intermittent Theta-Burst Transcranial Magnetic Stimulation

## Key facts

- **NCT ID:** NCT06669182
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2026-03-10
- **Final completion:** 2026-04-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669182, "Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06669182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*